Overview

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.

Phase:

Phase 4

Details

Lead Sponsor:

Theravance Biopharma

Collaborator:

Mylan Inc.

Treatments:

Tiotropium Bromide